SCHEMBL10112451

SCHEMBL10112451

CCN1CCN(c2cccc(-c3ccc(Br)cc3)n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.49
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR7 P34969 1/20 0.45
DRD3 P35462 1/20 0.45
CNR1 P21554 1/20 0.45
SMN1; SMN2 Q16637 5/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
DUSP3 P51452 1/20 0.42
PTPN5 P54829 1/20 0.42
PTPN11 Q06124 1/20 0.42
RAB9A P51151 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112458 0.80 TNF (0.43) HRH3HTR1ADRD2DRD4HTR2A
SCHEMBL30818920 0.79 HRH3 (0.56) HRH3DRD2DRD3SMN1; SMN2CYP1A2
SCHEMBL10112454 0.79 HRH3 (0.56) HRH3DRD2DRD3SMN1; SMN2CYP1A2
SCHEMBL10112497 0.78 CNR1 (0.50) CNR1SMN1; SMN2ALDH1A1CYP1A2CYP2D6
SCHEMBL3869622 0.78 HTR7 (0.47) HRH3DRD2DRD4HTR7DRD3
SCHEMBL10112496 0.77 CNR1 (0.49) CNR1SMN1; SMN2ALDH1A1CYP1A2CYP2D6
SCHEMBL13362635 0.77 CNR1 (0.46) HTR1ADRD2DRD4HTR2AHTR2C
SCHEMBL10112358 0.77 HRH3 (0.48) HRH3DRD2HTR2ASMN1; SMN2ALDH1A1
SCHEMBL15267450 0.76 HRH3 (0.47) HRH3DRD2HTR2AALDH1A1CYP1A2
SCHEMBL10112464 0.75 HRH3 (0.50) HRH3CNR1SMN1; SMN2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
WO-2010054279-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 HRH3 2441/4885HTR1A 4163/4885DRD2 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.